Thoratec Corporation (THOR, Nasdaq) is the world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts. We have held shares of this company for years watching the technology develop for its LVAS (Left Ventricular Assist System). The company has received FDA Pre-Market Approval allowing the use of its HeartMate II LVAS for Destination Therapy. This simply means that the HeartMate II can take the place of a transplant, giving hope to heart failure patients. Testimonials in newspapers from patients have been spectacular. Hundreds of thousands of under-served advanced-stage heart failure patients will eventually have access to this device. We strongly suggest that investors look up the company on the web to get a feel for the potential of this device. Analysts have begun to recommend the stock. Ten recommend it as a ‘Buy,’ three as a ‘Buy/Hold,’ and seven as a ‘Hold.’ The high for the year is $33.28 with a low of $22.42. We look forward to continued company growth and see THOR as one of our core positions.
Sean Christian, The Personal Capitalist, 6911 South 66th East Ave., Suite 301, Tulsa, Oklahoma 74133
